Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alterity Therapeutics Ltd

ATHE
Current price
2.05 USD -0.4 USD (-16.33%)
Last closed 2.45 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 25 666 288 USD
Yield for 12 month -29.07 %
1Y
3Y
5Y
10Y
15Y
ATHE
21.11.2021 - 28.11.2021

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Address: 350 Collins Street, Melbourne, VIC, Australia, 3000

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7 USD

P/E ratio

Dividend Yield

Current Year

Last Year

+2 272 568 USD

Current Quarter

Last Quarter

Current Year

Last Year

+2 110 819 USD

Current Quarter

Last Quarter

Key Figures ATHE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -12 832 270 USD
Operating Margin TTM -348.4 %
PE Ratio
Return On Assets TTM -28.94 %
PEG Ratio
Return On Equity TTM -53.72 %
Wall Street Target Price 7 USD
Revenue TTM 3 431 217 USD
Book Value 0.006 USD
Revenue Per Share TTM 0.6 USD
Dividend Share
Quarterly Revenue Growth YOY -20.3 %
Dividend Yield
Gross Profit TTM 3 631 266 USD
Earnings Share -2.73 USD
Diluted Eps TTM -2.73 USD
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ATHE

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ATHE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 09.01.2023
Dividend Date

Stock Valuation ATHE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 113.9898
Price Sales TTM 7.4802
Enterprise Value EBITDA -0.728
Price Book MRQ 1.7291

Financials ATHE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ATHE

For 52 weeks

1.55 USD 5.41 USD
50 Day MA 1.92 USD
Shares Short Prior Month 26 389
200 Day MA 2.38 USD
Short Ratio 0.77
Shares Short 23 055
Short Percent 2.25 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds


M

MDAXEX

208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics

Metals


Gold

2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics